Form 4: Humacyte Director Michael T. Constantino Acquires 4,600 Shares

Director Michael T. Constantino of Humacyte, Inc. purchased 4,600 shares of common stock at a price of $4.3872 per share on December 4, 2024.

Summary

• Michael T. Constantino, a director at Humacyte, Inc., acquired 4,600 shares of the company's common stock.
• The transaction occurred on December 4, 2024.
• The purchase price was $4.3872 per share.
• Following the transaction, Mr. Constantino directly owns 16,950 shares of Humacyte common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as a director purchasing shares can be seen as a positive sign, but it's a routine transaction.

Positives

• A director's purchase of company stock can be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is a routine disclosure for insider transactions and is common in the biotech industry.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies, and this transaction is consistent with typical insider trading activity.
• Similar filings are made by directors and officers of other biotech companies when they buy or sell shares of their company's stock.

Stakeholder Impact

• The purchase may have a slightly positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates

Keywords

Humacyte, insider trading, stock purchase, common stock, director, Michael T. Constantino, Form 4